| Patients Characteristics | n = 35 |
|---|---|
| Age (range) | 48 (21-76) |
| Sex (M/F) | 19/16 |
| Disease | |
| AML | 18 |
| ALL | 8 |
| CML | 3 |
| Myelofibrosis | 1 |
| Hodgkin Lymphoma | 3 |
| Non Hodgkin Lymphoma | 3 |
| Δότης | |
| Sibling | 6 |
| WMUD | 16 |
| MMUD | 8 |
| Haplo | 5 |
| Type of vaccine, mRNA/viral vector based | 32 (91%)/3 (9%) |
| Median d + of vaccination after allo-HCT (range) | 913.5 (137-4086) |
| SARS-Cov-2-IgG, positive/negative | 30 (86%)/5 (14%) |
| Measurement IgG levels after vaccination (range) | 171 (14-257) |
| Immunereconstitution at vaccination (range) | |
| CD20 | 172 (0-2168) |
| CD4 | 338 (72-1316) |
| CD8 | 637 (196-2168) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.